The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells

[1]  Huanming Yang,et al.  Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways , 2015, Tumor Biology.

[2]  N. Potter,et al.  Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma , 2014, Leukemia.

[3]  Liliana Goumnerova,et al.  Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma , 2014, Nature Genetics.

[4]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.

[5]  Zhixiang Wang,et al.  Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells , 2014, BMC Cancer.

[6]  B. Giusti,et al.  EXCAVATOR: detecting copy number variants from whole-exome sequencing data , 2013, Genome Biology.

[7]  Yongjun Zhao,et al.  Clonal evolution of high‐grade serous ovarian carcinoma from primary to recurrent disease , 2013, The Journal of pathology.

[8]  R. Kurzrock,et al.  BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance , 2013, Oncotarget.

[9]  CoNVEX: copy number variation estimation in exome sequencing data using HMM , 2013, BMC Bioinformatics.

[10]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[11]  I. Henderson,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials: Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (Clinical Trial Service Unit (CTSU), Oxford, UK) Lancet 379:432-444, 2012§ , 2013 .

[12]  N. Mao,et al.  Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo. , 2013, Oncology reports.

[13]  E. Cartwright,et al.  Disruption of the interaction between PMCA2 and calcineurin triggers apoptosis and enhances paclitaxel-induced cytotoxicity in breast cancer cells. , 2012, Carcinogenesis.

[14]  Wenjing Zhang,et al.  Establishment of Paclitaxel-Resistant Cell Line and the Underlying Mechanism on Drug Resistance , 2012, International Journal of Gynecologic Cancer.

[15]  Bing-he Xu,et al.  TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy , 2012, Breast Cancer Research and Treatment.

[16]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[17]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[18]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[19]  Bradley P. Coe,et al.  Copy number variation detection and genotyping from exome sequence data , 2012, Genome research.

[20]  Jason Li,et al.  CONTRA: copy number analysis for targeted resequencing , 2012, Bioinform..

[21]  Duc-Hau Le,et al.  GPEC: A Cytoscape plug-in for random walk-based gene prioritization and biomedical evidence collection , 2012, Comput. Biol. Chem..

[22]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[23]  D. Cutter,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.

[24]  C. Sotiriou,et al.  HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. , 2011, The Lancet. Oncology.

[25]  John Quackenbush,et al.  Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV , 2011, Bioinform..

[26]  G. Di,et al.  The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures , 2011, Breast Cancer Research and Treatment.

[27]  C. Hsieh,et al.  The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. , 2011, Molecular pharmaceutics.

[28]  Matko Bosnjak,et al.  REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms , 2011, PloS one.

[29]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[30]  N. J. Fauzee.  Taxanes: promising anti-cancer drugs. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[31]  A. Tsalenko,et al.  SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance , 2010, The Pharmacogenomics Journal.

[32]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[33]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[34]  Z. Bacso,et al.  Multidrug resistance through the spectacle of P-glycoprotein. , 2009, Current cancer drug targets.

[35]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[36]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[37]  Israel Steinfeld,et al.  BMC Bioinformatics BioMed Central , 2008 .

[38]  Hong-xia Li.  [Expression of COP9, JAK2, HSP and NADH in ovarian carcinoma tissues after taxol-chemotherapy and their significance]. , 2008, Zhonghua fu chan ke za zhi.

[39]  C. Criscitiello,et al.  Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[41]  Keisuke Tanaka,et al.  p180 is involved in the interaction between the endoplasmic reticulum and microtubules through a novel microtubule-binding and bundling domain. , 2007, Molecular biology of the cell.

[42]  Zohar Yakhini,et al.  Discovering Motifs in Ranked Lists of DNA Sequences , 2007, PLoS Comput. Biol..

[43]  Robin L. Jones,et al.  Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer , 2007, Breast Cancer Research and Treatment.

[44]  R. Callaghan,et al.  Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. , 2006, Current opinion in pharmacology.

[45]  Ravinder Singh,et al.  Fast-Find: A novel computational approach to analyzing combinatorial motifs , 2006, BMC Bioinformatics.

[46]  R. Simes,et al.  A systematic review of taxane-containing regimens for metastatic breast cancer , 2005, British Journal of Cancer.

[47]  N. Haites,et al.  Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines. , 2005, European journal of cancer.

[48]  Z. Duan,et al.  MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines. , 2004, Gene.

[49]  Yihong Ma,et al.  E2F4 deficiency promotes drug-induced apoptosis , 2004, Cancer biology & therapy.

[50]  R. Schreiber,et al.  Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. , 2001, Cancer research.

[51]  B. Trock,et al.  Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. , 1997, Journal of the National Cancer Institute.

[52]  James B. Mitchell,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. , 1987, Cancer research.

[53]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.